Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?

abstract：:Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

更新日期：2010-01-01 00:00:00

abstract：:In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

journal_title：Current vascular pharmacology

authors： Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

更新日期：2012-11-01 00:00:00

abstract：:Postprandial hypertriglyceridaemia, defined as an increase in plasma triglyceride-containing lipoproteins following a fat meal, is a potential risk predictor of atherosclerotic cardiovascular disease and other chronic diseases. Several non-modifiable factors (genetics, age, sex and menopausal status) and lifestyle fac...

journal_title：Current vascular pharmacology

authors： Kolovou GD,Watts GF,Mikhailidis DP,Pérez-Martínez P,Mora S,Bilianou H,Panotopoulos G,Katsiki N,Ooi TC,Lopez-Miranda J,Tybjærg-Hansen A,Tentolouris N,Nordestgaard BG

更新日期：2019-01-01 00:00:00

abstract：:This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Elisaf MS

更新日期：2014-01-01 00:00:00

abstract：:Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...

journal_title：Current vascular pharmacology

authors： Breen DM,Giacca A

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...

journal_title：Current vascular pharmacology

authors： Georgianos PI,Vaios V,Eleftheriadis T,Zebekakis P,Liakopoulos V

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:The primary objective of this study was to evaluate the impact of polypharmacy on primary and secondary adherence to evidence-based medication (EBM) and to measure factors associated with non-adherence among patients who underwent percutaneous coronary intervention (PCI). METHODS:We conducted a retrospectiv...

journal_title：Current vascular pharmacology

authors： Mohammed S,Arabi A,El-Menyar A,Abdulkarim S,AlJundi A,Alqahtani A,Arafa S,Al Suwaidi J

更新日期：2016-01-01 00:00:00

abstract：:Central arterial systolic blood pressure is a very important factor in the pathophysiology of cardiovascular diseases. Central arterial pressure is a better predictor of cardiovascular risk than peripheral brachial blood pressure. Measurement of central blood pressure is useful for a diagnosis of spurious systolic hyp...

journal_title：Current vascular pharmacology

authors： Stepień M,Banach M,Jankowski P,Rysz J

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE:This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. M...

journal_title：Current vascular pharmacology

authors： Kreutz R,Scholze J,Douros A

更新日期：2018-01-26 00:00:00

abstract：:Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

journal_title：Current vascular pharmacology

authors： De Backer D,Scolletta S

更新日期：2013-03-01 00:00:00

abstract：:Several cellular and molecular mechanisms have been implicated in the development of myocardial dysfunction and low cardiac output in pediatric patients undergoing heart surgery. Ischemia- reperfusion injury with alterations in calcium homeostasis as well as mitochondrial function has been strongly related to myocyte ...

journal_title：Current vascular pharmacology

authors： Bautista-Hernandez V,Karamanlidis G,McCully JD,Del Nido PJ

更新日期：2016-01-01 00:00:00

abstract：:Chronic venous disease (CVeD) is a debilitating condition that affects millions of individuals worldwide. The condition can result in varicose veins, or advance to severe skin changes and venous ulceration. The fundamental basis for CVeD is inflammation within the venous circulation and that it is subjected to increas...

journal_title：Current vascular pharmacology

authors： Mannello F,Ligi D,Canale M,Raffetto JD

更新日期：2014-01-01 00:00:00

abstract：:Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI). Dual antiplatelet therapy is mandated for pa...

journal_title：Current vascular pharmacology

authors： Kassimis G,Raina T,Alexopoulos D

更新日期：2019-01-01 00:00:00

abstract：UNLABELLED:Hif-1α, a master regulator of ischemia-responsive gene induction, controls pro-angiogenic gene expression of VEGF-A, flt-1, IGF-1 and erythropoietin, rendering its overexpression an attractive tool for therapeutic neovascularization. Utilizing an adenoviral vector system, we investigated the efficacy of sele...

journal_title：Current vascular pharmacology

authors： Hinkel R,Lebherz C,Fydanaki M,Wuchrer A,El-Aouni C,Thormann M,Thein E,Kupatt C,Boekstegers P

更新日期：2013-01-01 00:00:00

abstract：:Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...

journal_title：Current vascular pharmacology

authors： Lenglet S,Montecucco F,Mach F

更新日期：2015-01-01 00:00:00

abstract：:Platelet aggregation induced by stirring of a platelet suspension after activation by the exogenous addition of stimulants, such as ADP, epinephrine and thrombin, has long been used as a platelet function test, and for the screening of antiplatelet agents. Since platelet aggregation has been demonstrated to be mediate...

journal_title：Current vascular pharmacology

authors： Goto S

更新日期：2004-01-01 00:00:00

abstract：:During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. e...

journal_title：Current vascular pharmacology

authors： Kolovou G,Barzilai N,Caruso C,Sikora E,Capri M,Tzanetakou IP,Bilianou H,Avery P,Katsiki N,Panotopoulos G,Franceschi C,Benetos A,Mikhailidis DP

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Volatile Anaesthetics (VA) are commonly used worldwide for induction and/or maintenance of general anaesthesia. They act in the central nervous system to reduce sensation and motor response during surgical and invasive diagnostic procedures. VAs also have some non-anaesthetic properties in the brain when adm...

journal_title：Current vascular pharmacology

authors： Krzych LJ,Szczepanska AJ

更新日期：2018-01-01 00:00:00

abstract：:High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

journal_title：Current vascular pharmacology

authors： Biscetti F,Ghirlanda G,Flex A

更新日期：2011-11-01 00:00:00

abstract：:Monoclonal antibodies have been developed to optimize treatment effects in various malignant and nonmalignant conditions, by selectively targeting key components of the underlying pathophysiologic processes. Rituximab, a chimeric anti-CD20 antibody has revolutionized treatment of malignant lymphomas, extending remissi...

journal_title：Current vascular pharmacology

authors： Ziakas PD,Kopterides P,Voulgarelis M

更新日期：2010-01-01 00:00:00

abstract：:Both endothelin(ET)-1 and oxidative stress have been the subjects of intense investigation within the cardiovascular field over the past decade and a half, yet little is known about the precise relationship between these important modulators of vascular function. There is a firm evidence that ET-1 can stimulate the pr...

journal_title：Current vascular pharmacology

authors： Pollock DM,Pollock JS

更新日期：2005-10-01 00:00:00

abstract：BACKGROUND:In various cardiac diseases, thrombembolism constitutes a major risk, and in these patients clinically silent microembolic signals (MES) are detectable within the transcranial Doppler frequency spectrum (TCD) of the major brain arteries. MES are already an accepted surrogate parameter of the future risk of s...

journal_title：Current vascular pharmacology

authors： Dittrich R,Ringelstein EB

更新日期：2008-10-01 00:00:00

abstract：:Atherosclerosis (also known as arteriosclerotic vascular disease) is a chronic inflammatory disease of the arterial wall, characterized by the formation of lipid-laden lesions. The activation of endothelial cells at atherosclerotic lesion-prone sites in the arterial tree results in the up-regulation of cell adhesion m...

journal_title：Current vascular pharmacology

authors： Araldi E,Chamorro-Jorganes A,van Solingen C,Fernández-Hernando C,Suárez Y

更新日期：2013-05-13 00:00:00

abstract：:The incidence of cardiovascular disease is low in healthy premenopausal women and increases with age especially after the menopause; this difference has been attributed to the loss of endogenous estrogen. Atherosclerosis is a chronic inflammatory condition of the vascular wall that may result in an acute clinical even...

journal_title：Current vascular pharmacology

authors： Bechlioulis A,Naka KK,Calis KA,Makrigiannakis A,Michalis L,Kalantaridou SN

更新日期：2010-03-01 00:00:00

abstract：:Obesity is a risk factor for complications of atherosclerotic vascular disease such as myocardial infarction and stroke. Recent studies have demonstrated that the vascular risk associated with obesity is correlated particularly with visceral adiposity. These clinical observations indicate that various adipose tissue d...

journal_title：Current vascular pharmacology

authors： Ohman MK,Wright AP,Wickenheiser KJ,Luo W,Eitzman DT

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...

journal_title：Current vascular pharmacology

authors： Shehab A,Al-Rasadi K,Arafah M,Al-Hinai AT,Al Mahmeed W,Bhagavathula AS,Al Tamimi O,Al Herz S,Al Anazi F,Al Nemer K,Metwally O,Alkhadra A,Fakhry M,Elghetany H,Medani AR,Yusufali AH,Al Jassim O,Al Hallaq O,Baslaib FOAS

更新日期：2018-01-01 00:00:00

abstract：INTRODUCTION:Obstructive Sleep Apnoea (OSA) constitutes the most prevalent form of abnormal respiratory control during sleep in adults. Evidence linked OSA to cardiovascular disease, and the role of OSA in abnormal Blood Pressure (BP) control has been extensively studied. Although longitudinal trials suggest a causativ...

journal_title：Current vascular pharmacology

authors： Wolf J,Narkiewicz K

更新日期：2017-01-01 00:00:00

abstract：:Many patients with hypertension will require multiple antihypertensive drugs to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combinations (SPCs) in patients with mild-to-moderate hypertension who were non-responsive to aliskiren mono...

journal_title：Current vascular pharmacology

authors： Glorioso N,Thomas M,Troffa C,Argiolas G,Patel S,Baek I,Zhang J

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

journal_title：Current vascular pharmacology

authors： Rubboli A,Patti G

更新日期：2018-01-01 00:00:00

abstract：:Gestational diabetes mellitus (GDM) is a syndrome compromising the health of the mother and the fetus. Endothelial damage and reduced metabolism of the vasodilator adenosine occur and fetal hyperinsulinemia associated with deficient insulin response and a metabolic rather than mitogenic phenotype is characteristic of ...

journal_title：Current vascular pharmacology

authors： Guzmán-Gutiérrez E,Abarzúa F,Belmar C,Nien JK,Ramírez MA,Arroyo P,Salomón C,Westermeier F,Puebla C,Leiva A,Casanello P,Sobrevia L

更新日期：2011-11-01 00:00:00